Prescient’s (ASX: PTX) abstract for PTX-100 features on ASH website - Kalkine Media

November 06, 2023 06:20 PM AEDT | By Sonal Goyal

Prescient’s (ASX: PTX) abstract for PTX-100 features on ASH website — Image source: Company website

Recent News

What's next for the S&P 500 after Friday's inflation data

Galaxy Macau, The World Class Integrated Resort, Unveils the "Experien...

Summit Planners: Understanding the Terms in a Will

Flash News: OKX Wallet Integrates with Side Protocol

Highlights

Prescient Therapeutics’ abstract for PTX-100 has been published on the American Society of Hematology (ASH) website

PTX-100 Phase 1b study is ongoing with patients with refractory and relapsed TCL

The trial results are anticipated to be released on the ASX in December 2023

Prescient Therapeutics Limited (ASX: PTX) informed that its PTX-100’s abstract has been published on the American Society of Hematology (AXH) website before the scheduled presentation on 9 December 2023.

The abstract concerns the interim results from the ongoing Phase 1b study examining PTX-100 in patients with relapsed and refractory T-cell lymphoma (TCL).

Data source: Company update

The abstract highlights that as at the cut-off date, total 14 patients were treated, of which 10 patients underwent response assessment after four-cycle therapy and the overall response rate was 40%. For the abstract, data cut off was 10 July 2023 and the study is going on.

Data source: Company update

The results of the PTX-100 Phase 1b trial that comprises additional and updated data are likely to be announced in December 2023, after the ASH presentation.

PTX shares traded at AU$0.056 apiece at the time of writing on 6 November 2023.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024

Markets

Disclaimer